ReShape Lifesciences Inc (ReShape) formerly Obalon Therapeutics Inc, designs, develops and commercializes minimally invasive medical devices to treat obesity and metabolic diseases. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. ReShape Vest system is a implanted device allows weight reduction while keeping the stomach in place. It provides ReShapeCare virtual health coaching programme, which encourages healthy lifestyle modifications for all patients undergoing medically assisted weight reduction, and ReShape Diabetes Bloc-Stim Neuromodulation, a preclinical technology being developed for the treatment of type 2 diabetes mellitus. ReShape is headquartered in San Clemente, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company ReShape Lifesciences Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
ReShape Lifesciences Inc Company Overview
ReShape Lifesciences Inc Company Snapshot
ReShape Lifesciences Inc Pipeline Products and Ongoing Clinical Trials Overview
ReShape Lifesciences Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
ReShape Lifesciences Inc, Recent Developments
Nov 12, 2024: Reshape Lifesciences Receives Health Canada Approval for Its Next-Generation Lap-Band 2.0 Flex
Nov 11, 2024: ReShape Lifesciences Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes B
Mar 28, 2024: Reshape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
Mar 04, 2024: ReShape Lifesciences Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band 2.0 FLEX
Feb 22, 2024: Reshape Lifesciences Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex
Jan 24, 2024: ReShape Lifesciences Conducts Bariatric Fellows Training for its Lap-Band System, Highlighting the Next-Generation Lap-Band 2.0 FLEX
Dec 12, 2023: ReShape Lifesciences Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band 2.0 FLEX
Nov 06, 2023: ReShape Lifesciences to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
Sep 22, 2023: ReShape Lifesciences Announces Participation in the LD Micro Main Event XVI
Sep 19, 2023: ReShape Lifesciences Significantly Strengthens Patent Portfolio Related to its Obalon Balloon System
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
ReShape Lifesciences Inc Pipeline Products and Ongoing Clinical Trials Overview
ReShape Lifesciences Inc Pipeline Products by Equipment Type
ReShape Lifesciences Inc Pipeline Products by Indication
ReShape Lifesciences Inc, Key Facts
ReShape Lifesciences Inc, Major Products and Services
ReShape Lifesciences Inc Number of Pipeline Products by Development Stage
ReShape Lifesciences Inc Pipeline Products Summary by Development Stage
Diabetes Bloc-Stim Neuromodulation Device - Product Status